A multicenter population-based experience with abiraterone acetate (AA) in patients with metastatic castration resistant prostate cancer (mCRPC)

被引：2
|
作者：
Clayton, Ravinder
Heng, Daniel Yick Chin
Wu, Jackson S. Y.
Zielinski, Rob
North, Scott A.
Emmenegger, Urban
Hotte, Sebastien J.
Al-Shamsi, Humaid Obaid
Chen, Leo
Eigl, Bernhard J.
机构：
[1] Tom Baker Canc Clin, Calgary, AB, Canada
[2] British Columbia Canc Agcy, Vancouver Canc Ctr, Vancouver, BC V5Z 4E6, Canada
[3] Cross Canc Inst, Edmonton, AB T6G 1Z2, Canada
[4] Univ Toronto, Sunnybrook Odette Canc Ctr, Toronto, ON, Canada
[5] Juravinski Canc Ctr, Hamilton, ON, Canada
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 06期
关键词：
D O I：
10.1200/jco.2013.31.6_suppl.113
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
113
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Assessment of prognostic factors in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with abiraterone acetate (AA) after docetaxel (DOC).
    Cavaliere, Carla
    Caffo, Orazio
    Ortega, Cinzia
    D'aniello, Carmine
    Di Napoli, Marilena
    Cecere, Sabrina Chiara
    Della Pepa, Chiara
    Crispo, Anna
    Maines, Francesca
    Ruatta, Fiorella
    Iovane, Gelsomina
    Montella, Maurizio
    Pignata, Sandro
    Facchini, Gaetano
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [22] Effects of 6 months of abiraterone acetate (AA) on muscle and adipose mass in men with metastatic castration-resistant prostate cancer (mCRPC)
    Brondfield, Samuel Craig
    Weinberg, Vivian K.
    Koepfgen, Kathryn M.
    Molina, Arturo
    Ryan, Charles J.
    Small, Eric Jay
    Harzstark, Andrea Lynne
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (05)
  • [23] Results of a phase II trial of abiraterone acetate (AA) combined with dutasteride (DUT) for men with metastatic castration resistant prostate cancer (mCRPC).
    McKay, Rana R.
    Werner, Lillian
    Zukotynski, Katherine A.
    Domachevsky, Liran
    Elfiky, Aymen
    Pomerantz, Mark M.
    Bubley, Glenn J.
    Montgomery, Robert B.
    Kantoff, Philip W.
    Taplin, Mary-Ellen
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04)
  • [24] Phase 1b study of abiraterone acetate (AA) and docetaxel (D) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).
    Tagawa, Scott T.
    Posadas, Edwin M.
    Bruce, Justine Yang
    Lim, Emerson A.
    Petrylak, Daniel Peter
    Peng, Weimin
    Maul, Raymond Scott
    Smit, Hans W.
    Tran, Namphuong
    Nanus, David M.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [25] Cabazitaxel in metastatic castrate resistant prostate cancer (mCRPC) in the era of enzalutamide (ENZA) and abiraterone acetate (AA).
    Body, Amy
    Pranavan, Gane
    Malik, Laeeq
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [26] Neutrophil to lymphocyte ratio (NLR) impact on the survival and response duration of patients with metastatic castration resistant prostate cancer (mCRPC) treated with abiraterone acetate (AA)
    Mansinho, A. B.
    Macedo, D.
    Fernandes, I. C.
    Quintela, A.
    Costa, L. A. M.
    ANNALS OF ONCOLOGY, 2016, 27
  • [27] ARN-509 in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) with and without prior abiraterone acetate (AA) treatment.
    Rathkopf, Dana E.
    Antonarakis, Emmanuel S.
    Shore, Neal D.
    Tutrone, Ronald F.
    Alumkal, Joshi J.
    Ryan, Charles J.
    Saleh, Mansoor N.
    Hauke, Ralph J.
    Bandekar, Rajesh
    Maneval, Edna Chow
    De Boer, Carla
    Todd, Mary Beth
    Yu, Margaret K.
    Scher, Howard I.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [28] When the time matters: Metastatic Castration Resistant Prostate Cancer (mCRPC) patients long responders to Abiraterone acetate (AA) in post-docetaxel setting
    Procopio, G.
    Porcu, L.
    Grassi, P.
    De Giorgi, U.
    Galli, L.
    Caffo, O.
    Boccardo, F.
    Facchini, G.
    De Vincenzo, F.
    Zaniboni, A.
    Chiuri, V.
    Fratino, L.
    Santini, D.
    Adamo, V.
    De Vivo, R.
    Di Nota, A.
    Messina, C.
    Ricotta, R.
    de Braud, F.
    Verzoni, E.
    ANNALS OF ONCOLOGY, 2015, 26 : 59 - 59
  • [29] Impact of prior response to abiraterone acetate (AA) on subsequent activity of docetaxel (D) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts).
    Azad, Arun
    Lester, Renee
    Heng, Daniel Yick Chin
    Eigl, Bernhard J.
    Chi, Kim N.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04)
  • [30] IMPACT OF ABIRATERONE ACETATE IN THE POSTDOCETAXEL SETTING ON THE SURVIVAL OF METASTATIC CASTRATION-RESISTANT PROSTATE CANCER PATIENTS: A POPULATION-BASED STUDY IN QUEBEC
    Dragomir, Alice
    Rocha, Joice
    Vanhuyse, Marie
    Cury, Fabio
    Hu, Jason
    Prevost, Noemie
    Aprikian, Armen
    JOURNAL OF UROLOGY, 2017, 197 (04): : E453 - E453
12345